New method detects residual cancer cells
Amplicon fusion sites polymerase chain reaction (AFS-PCR) assay can detect and quantify human neuroblastoma cells in human blood and bone marrow samples.
Prognosis
TPF better than PF regimen for HNC
A three-drug treatment for head and neck cancer (HNC) improves long-term survival so significantly that researchers are calling for the trio to become the standard of care for patients suitable for first-line therapy.
Iniparib impressive in triple-negative breast cancer
Adding iniparib to gemcitabine and carboplatin significantly increased clinical benefit and survival—but not toxic effects—in women with metastatic triple-negative breast cancer.
Gene deletion may explain many cases of glioblastoma
An important gene deletion appears to occur in as many as 1 of every 4 cases of glioblastoma—the most common adult brain cancer—scientists have found.
FDA moves to withdraw breast-cancer indication for Avastin
The FDA today recommended to remove the breast-cancer indication from the label of Avastin (bevacizumab) after reviewing the results of four clinical studies.
Study defines follow-up standards for early-stage lung cancer
Long-term follow-up strategies can be defined for patients with early-stage lung cancer, according to a study published in the Journal of Thoracic Oncology (2010 Aug;5(8):1246-50).
Super-sensitive tests helps predict chances of long-time survival of prostate cancer patients
Prostate cancer recurrence can be predicted using an ultrasensitive test, according to a study presented at the 2010 Annual Meeting of the American Urological Association.
Survival in stage II and stage III colon cancer patients improves after 1995
Colon cancer patients treated after 1995 experience improved overall survival compared to patients treated before 1995, according to a study presented at the 2010 Annual Meeting of the American Society of Clinical Oncology.
Research demonstrates prognostic significance of biomarker for non-small cell lung carcinomas
Patterns of a novel cancer biomarker in non-small lung carcinomas (NSCLC) may be used to help predict patient outcome, according to a study published in the Journal of Thoracic Oncology (2010;5(5):649-57).
